Skip to content
10-Q

Quarterly Report

Juno Therapeutics, Inc.

0001594864-17-000022

← back to feed
Filed
May 4, 2017 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2017 · Apr 27, 2017 106.1M sh
Capex Q1 2017 · Mar 31, 2017 $21.15M
Capex Q1 2017 · Mar 31, 2016 $4.04M
Operating Cash Flow Q1 2017 · Mar 31, 2017 −$53.93M
Operating Cash Flow Q1 2017 · Mar 31, 2016 −$58.17M
Cash And Equivalents Q1 2017 · Mar 31, 2017 $205.7M
Cash And Equivalents Q1 2017 · Dec 31, 2016 $187.89M
Cash And Equivalents Q1 2017 · Mar 31, 2016 $316.01M
Cash And Equivalents Q1 2017 · Dec 31, 2015 $252.4M
Stockholders Equity Q1 2017 · Mar 31, 2017 $1.02B
Stockholders Equity Q1 2017 · Dec 31, 2016 $1.08B
Current Liabilities Q1 2017 · Mar 31, 2017 $122.6M
Current Liabilities Q1 2017 · Dec 31, 2016 $114.89M
Current Assets Q1 2017 · Mar 31, 2017 $779.52M
Current Assets Q1 2017 · Dec 31, 2016 $772.33M
Total Assets Q1 2017 · Mar 31, 2017 $1.31B
Total Assets Q1 2017 · Dec 31, 2016 $1.35B
Sga Expense Q1 2017 · Mar 31, 2017 $20.73M
Sga Expense Q1 2017 · Mar 31, 2016 $15.95M
Rd Expense Q1 2017 · Mar 31, 2017 $82.92M
Rd Expense Q1 2017 · Mar 31, 2016 $73.72M
Net Income Q1 2017 · Mar 31, 2017 −$82.2M
Net Income Q1 2017 · Mar 31, 2016 −$71.14M
Operating Income Q1 2017 · Mar 31, 2017 −$84.32M
Operating Income Q1 2017 · Mar 31, 2016 −$79.9M
Revenue Q1 2017 · Mar 31, 2017 $19.33M
Revenue Q1 2017 · Mar 31, 2016 $9.78M